欧美熟妇乱子伦XX视频,久热这里只有精品99在线观看

Prorenoate potassium

NMR下載 COA and HPLC MSDS下載
names：
potassium 3-((4aS,4bS,6aS,7R,9aS,9bR,9cS,10aR)-7-hydroxy-4a,6a-dimethyl-2-oxo-2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,9c,10,10a-hexadecahydrocyclopenta[a]cyclopropa[l]phenanthren-7-yl)propanoate
CAS號：
49847-97-4
MDL Number：
MF(分子式)： C23H31KO4 MW(分子量)： 410.59
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	potassium 3-((4aS,4bS,6aS,7R,9aS,9bR,9cS,10aR)-7-hydroxy-4a,6a-dimethyl-2-oxo-2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,9c,10,10a-hexadecahydrocyclopenta[a]cyclopropa[l]phenanthren-7-yl)propanoate
英文別名	Prorenoate potassium; Sc 23992; Sc-23992; Sc23992;
CAS號	49847-97-4
Inchi	InChI=1S/C23H32O4.K/c1-21-7-3-13(24)11-18(21)14-12-15(14)20-16(21)4-8-22(2)17(20)5-9-23(22,27)10-6-19(25)26;/h11,14-17,20,27H,3-10,12H2,1-2H3,(H,25,26);/q;+1/p-1/t14-,15-,16+,17+,20-,21+,22+,23-;/m1./s1
InchiKey	NLSAMWIBIQWHTK-TZHLAWPMSA-M
分子式 Formula	C23H31KO4
分子量 Molecular Weight	410.59
溶解度Solubility
性狀	Solid powder
儲藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產(chǎn)品說明	Prorenoate potassium(CAS:49847-97-4):僅限應用于工業(yè)或者科學研究過程中非醫(yī)療目的，不應用于人類或動物的臨床診斷以及治過程療，該產(chǎn)品非藥用，非食用。
Introduction	Prorenoate potassium is is a synthetic steroidal antimineralocorticoid.
Application1
Application2
Application3

警示圖
危險性	Warning
危險性警示
安全聲明
安全防護
備注

[1]McInnes GT, Shelton JR, Harrison IR, Perkins RM, Palmer RF. Comparison of prorenoate potassium and spironolactone after repeated doses and steady state plasma levels of active metabolites. Br J Clin Pharmacol. 1982 Feb;13(2):187-94. PubMed PMID: 7059416; PubMed Central PMCID: PMC1401979.

[2]McInnes GT, Harrison IR, Shelton JR, Perkins RM, Clarke JM. Relative potency of prorenoate potassium and spironolactone in attenuating diuretic induced hypokalaemia. Br J Clin Pharmacol. 1984 Aug;18(2):169-74. PubMed PMID: 6487456; PubMed Central PMCID: PMC1463509.

[3] Levine D, Ramsay L, Auty R, Branch R, Tidd M. Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone. Eur J Clin Pharmacol. 1976 Mar 22;09(5-6):381-6. PubMed PMID: 786663.

[4] Ramsay LE, Shelton JR, Tidd MJ. The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects. Br J Clin Pharmacol. 1976 Jun;3(3):475-82. PubMed PMID: 788750; PubMed Central PMCID: PMC2958760.

[5] Ramsay L, Harrison I, Shelton J, Tidd M. Relative potency of prorenoate and spironolactone in normal man. Clin Pharmacol Ther. 1975 Oct;18(4):391-400. PubMed PMID: 1100306.

6: McInnes GT, Shelton JR, Harrison IR. Steady-state relative potency of aldosterone antagonists: spironolactone and prorenoate. Clin Pharmacol Ther. 1981 May;29(5):679-86. PubMed PMID: 7214797.7: Lumb GD, Rust JH. The pathologic response of the liver and thyroid of the rat to potassium prorenoate (SC-23992). Toxicol Pathol. 1985;13(4):315-24. PubMed PMID: 3834584.8: Netchitailo P, Delarue C, Perroteau I, Jegou S, Tonon MC, Leroux P, Leboulenger F, Kusmierek MC, Capron MH, Vaudry H. Effect of aldosterone antagonists on mineralocorticoid synthesis in vitro. Inhibition of aldosterone production by prorenoate-K. Eur J Pharmacol. 1982 Feb 5;77(4):243-9. PubMed PMID: 6277668.9: Auty R, Branch RA, Cole EN, Levine D, Ramsay L. Prolactin, diuretics and urinary electrolytes in normal subjects. J Endocrinol. 1976 Aug;70(2):173-81. PubMed PMID: 965879.10: McInnes GT, Shelton JR, Ramsay LE, Harrison IR, Asbury MJ, Clarke JM, Perkins RM, Venning GR. Relative potency and structure activity relationships of aldosterone antagonists in healthy man: correlation with animal experience. Br J Clin Pharmacol. 1982 Mar;13(3):331-9. PubMed PMID: 6460516; PubMed Central PMCID: PMC1402118.1

對不起，暫無產(chǎn)品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開